
MacroGenics (MGNX) Stock Forecast & Price Target
MacroGenics (MGNX) Analyst Ratings
Bulls say
Macrogenics Inc. has demonstrated significant capability in antibody engineering and has developed a robust pipeline of promising product candidates, including its lead product MARGENZA for metastatic HER2-positive breast cancer. The company's strategic collaborations with global pharmaceutical and biotechnology firms enhance its market position and potential for future revenue generation, indicating a strong trajectory in the competitive biopharmaceutical landscape. Additionally, the anticipated increase in data flow from early-stage programs, coupled with the recent initiation of patient dosing in pivotal trials, suggests opportunities for non-dilutive capital through strategic partnerships, contributing to a positive outlook for the company's financial performance.
Bears say
Macrogenics Inc reported lower-than-expected revenue of $13 million, coupled with a significant GAAP net loss of $41 million, or $(0.65) per share, which exceeded initial and consensus estimates. The company's research and development expenditure amounted to $40 million, reflecting a 23% year-over-year decline, indicating potential challenges in its developmental pipeline. Additionally, the total operating expenses decreased by 19% year-over-year at $56 million, further highlighting concerns regarding the company’s financial health and operational efficiency amidst ongoing losses.
This aggregate rating is based on analysts' research of MacroGenics and is not a guaranteed prediction by Public.com or investment advice.
MacroGenics (MGNX) Analyst Forecast & Price Prediction
Start investing in MacroGenics (MGNX)
Order type
Buy in
Order amount
Est. shares
0 shares